The results showed that AZM significantly inhibited expression of TGF-β1 and phosphorylated Smad2 and Smad3 in the lung tissue of BLM-treated mice, while total Smad2 and Smad3 protein levels did not change (Figure 4). The gene discussed is SMAD3; the disease is Bloom syndrome.